Skip to content

Drug interactions

Linagliptin-metformin + Lorlatinib

Severity: Moderate

Linagliptin-metformin and Lorlatinib: moderate interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Lorlatinib is a moderate CYP3A4 inducer and may lower linagliptin exposure. This could reduce glycemic control, although linagliptin is eliminated mostly unchanged and the effect is modest.

What this interaction means in plain words

Linagliptin-metformin and Lorlatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.

Linagliptin-metformin belongs to Endocrine; Lorlatinib belongs to Oncology.

Evidence level: Low

Why it happens

Induction of CYP3A4 (and possibly P-gp) increases linagliptin clearance.

What to do

Monitor blood glucose and HbA1c after starting lorlatinib. Intensify antidiabetic therapy if control worsens.

What to ask your pharmacist

  • Should I take them at different times of day?
  • Does the dose of either medicine need to change?
  • Is there anything I should avoid, such as alcohol or certain foods, while on both?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Linagliptin-metformin and Lorlatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 7 days on the web. No card needed.

Frequently asked questions

Can I take Linagliptin-metformin with Lorlatinib?

MediHelp rates the interaction as moderate. Linagliptin-metformin and Lorlatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Lorlatinib is a moderate CYP3A4 inducer and may lower linagliptin exposure. This could reduce glycemic control, although linagliptin is eliminated mostly unchanged and the effect is modest.

How serious is the interaction between Linagliptin-metformin and Lorlatinib?

MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood glucose and HbA1c after starting lorlatinib. Intensify antidiabetic therapy if control worsens.

What other medicines interact with Linagliptin-metformin?

MediHelp also lists interactions of Linagliptin-metformin with, for example, Apalutamide, Carbamazepine, Contrast media. The full list is on the Linagliptin-metformin page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in